Vesugen

KED tripeptide bioregulatorCardio/Vascular

Evidence grade

DResearch/compounded/adjunct (no established FDA indication)

Cardiovascular · 0–5 · separate axis

Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeVascular bioregulator

MechanismLys-Glu-Asp tripeptide from the Khavinson family, studied for vascular-tissue signalling.

EffectsStudied for blood-vessel tissue maintenance.

DosingNo human dose established.

Bottom lineA vascular-targeted bioregulator with no Western clinical validation.

Not a dose · what the literature contains instead

Reported practice is 20 mg/day orally or 2–3 mg/day injected. These are community figures, not trial doses.

Batches on filenone

No tested batches on file.

Read with

The library records no pairings for this entry.

Cautions & interactions

Evidence is Russian observational and preclinical work from one research group. Independent Western clinical trials are essentially absent.

No interaction data published.

CV 1 of 5 — Vascular tissue is its stated target, but no cardiovascular outcome has been measured in a controlled trial.